ASX Healthcare Stocks - Stocks Down Under

CSL (ASX:CSL) Down 44% YTD at Decade Lows: Buying Opportunity or Falling Knife?

CSL Hits Decade Lows: Buy the Dip or Wait? CSL (ASX:CSL) shares slipped another 2% today, extending yesterday's brutal sell-off that pushed the stock to its lowest level since 2017.…

3 days ago

Amplia (ASX:ATX) Adds Ovarian Trial with ANZGOG After Narmafotinib Hits 35% Pancreatic Response Rate

Amplia Adds Ovarian Trial After Pancreatic Success Amplia Therapeutics (ASX:ATX) has opened a new chapter in its drug story. On 8 May, the small-cap biotech announced a partnership with the…

May 2026

GLP-1 Boom Hits ASX Healthcare: 3 ASX Healthcare Stocks Reshaped by Eli Lilly’s Blockbuster Quarter

ASX Healthcare Stocks Caught in the GLP-1 Storm After Eli Lilly's Blockbuster Quarter Eli Lilly (NYSE:LLY) just delivered a knockout first-quarter 2026 result on Thursday, with sales of its weight-loss…

May 2026

ResMed (ASX:RMD) Falls Despite Earnings Beat: Buy the Dip?

ResMed (ASX:RMD) just delivered what looked like a great quarter. Revenue jumped 11%, earnings climbed 21%, and the company beat analyst expectations. On paper, this should have been a green day…

Medical Developments (ASX:MVP) Surges 35% After Penthrox Drives Positive Cash Flow and European Expansion

Medical Developments International (ASX:MVP) jumped 35% on Friday to close at A$0.52 after a Q3 FY26 update that surprised the market on two fronts. The company delivered positive operating cash…

ASX Healthcare Sector Sheds 6% in a Day: 3 Stocks Now Trading at Bargain Levels

The ASX healthcare sector lost 6% in a single day on Wednesday, its worst session in years. The trigger was Cochlear (ASX:COH), which fell 40.7% to a decade-low of A$99.58…

Monash IVF (ASX:MVF) Rejects A$0.90 Soul Patts Bid: Shares Slide 6% on Second Knockback

Monash IVF Knockback Sends Shares Lower Monash IVF Group (ASX:MVF) shares slid nearly 6% to A$0.72 on Monday after the board rejected a revised A$0.90 per share takeover bid from…

Pro Medicus (ASX:PME) Banks A$80M in One Month: Is the 60% Selloff Finally a Buy?

Pro Medicus Secures A$80M Amid 60% Selloff Pro Medicus (ASX:PME) jumped 4.3% on Monday after securing a A$37 million contract renewal with Northwestern Medicine at higher per-exam fees than its…

Pro Medicus (ASX:PME) Rallies on $23m Maryland Contract. Is This the Dip Investors Should Be Buying?

Pro Medicus jumps on new US contract Pro Medicus (ASX:PME) jumped more than 8% on Wednesday after sealing a five-year, A$23 million contract with the University of Maryland Medical System.…

Mesoblast (ASX:MSB) Falls 7% Despite Record US$30.3M Ryoncil Quarter- Is This the Dip to Buy?

Mesoblast Shares Fall Despite Record Sales Mesoblast (ASX: MSB) shares fell around 7% on Tuesday, trading near A$1.98, after the company reported its best-ever quarterly Ryoncil sales. Net sales for…